Please ensure Javascript is enabled for purposes of website accessibility

United Therapeutics profit soars

United Therapeutics, of Silver Spring, a biotechnology company, nearly doubled its profit for 2014, boosted by a strong fourth quarter. United Therapeutics reported net income of $340.1 million, or $6.28 per diluted share, for the year, compared with $174.6 million and $3.28 for 2013. In the quarter ended Dec. 31, the firm posted net income of $115.9 million, or $2.17 per diluted share, compared with a net loss of $30.3 million and 60 cents for the prior-year period. Fourth-quarter revenue rose 20 percent, to $346.4 million from 2013’s $289.0 million for the same quarter. Revenue for year was nearly $1.3 billion, up 15 percent from $1.1 billion in 2013. United Therapeutics’ revenue benefited from the introduction of Orenitram, a blood pressure medication, during 2014. It brought in about $20.2 million.